CHICAGO — In this video, Andre Kydd, MD, PhD, discusses highlights in the field of prostate cancer, including biomarkers of response in treatment and data on new classes of therapeutic agents, presented at ASCO Annual Meeting.
“We look forward to providing more information on ways that these may ultimately start to effect clinical practice in the coming months and years,” Kydd, assistant professor of genitourinary medical oncology at Fox Chase Cancer Center, told Healio.

CHICAGO — In this video, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial, which assessed efficacy and safety of adjuvant giredestrant in premenopausal vs. postmenopausal women with breast cancer.
Findings from the study, which compared giredestrant (Genentech, Roche) with standard-of-care endocrine therapy in ER-positive, HER2-negative early breast cancer, were presented at ASCO Annual Meeting.
Regardless of menopause status, giredestrant improved survival for women with breast cancer.
“With the approval of adjuvant abemaciclib (Verzenio, Eli Lilly & Co.) and